Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.35 |
| ▸ | HRH1 | P35367 | 9/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28910385 | 0.98 | HRH1 (0.37) | HRH3HRH4HRH1HRH2PDPK1 | |
| SCHEMBL7075618 | 0.95 | HRH4 (0.33) | HRH3HRH4PDPK1SSTR1SSTR2 | |
| SCHEMBL11109785 | 0.84 | MAPT (0.31) | ALDH1A1 | |
| SCHEMBL27085316 | 0.82 | KCNH2 (0.43) | ALDH1A1 | |
| SCHEMBL8405599 | 0.81 | — | — | |
| SCHEMBL6131656 | 0.77 | SIRT2 (0.31) | ALDH1A1 | |
| SCHEMBL11389549 | 0.77 | TSHR (0.39) | ALDH1A1 | |
| SCHEMBL23846225 | 0.75 | HRH3 (0.39) | HRH3HRH4HRH1HRH2PDPK1 | |
| SCHEMBL12559910 | 0.73 | HRH3 (0.40) | HRH3HRH4HRH1HRH2PDPK1 | |
| SCHEMBL4231087 | 0.73 | SMN1; SMN2 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160841-A1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY MICRONEEDLE SYSTEM | NORTH CAROLINA STATE UNIVERSITY (US) | 2022-05-26 | — | — | US | disclosed |
| US-11191815-B2 | Glucose-responsive insulin delivery microneedle system | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3795143-A1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY SYSTEM USING HYPOXIA-SENSITIVE NANOCOMPOSITES | North Carolina State University (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3285750-B1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY SYSTEM USING HYPOXIA-SENSITIVE NANOCOMPOSITES | UNIV NORTH CAROLINA STATE (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20180110841-A1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY SYSTEM USING HYPOXIA-SENSITIVE NANOCOMPOSITES | NORTH CAROLINA STATE UNIVERSITY | 2018-04-26 | — | — | US | disclosed |
| EP-3285750-A1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY SYSTEM USING HYOXIA-SENSITIVE NANOCOMPOSITES | North Carolina State University (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172320-A1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY SYSTEM USING HYOXIA-SENSITIVE NANOCOMPOSITES | NORTH CAROLINA STATE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFER (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160841-A1 | GLUCOSE-RESPONSIVE INSULIN DELIVERY MICRONEEDLE SYSTEM | SLC2A3, SLC2A4, SLC2A8 | HRH3 86/4885HRH4 132/4885HRH1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.